Provided by Tiger Fintech (Singapore) Pte. Ltd.

OmniAb, Inc.

2.28
-0.1200-5.00%
Post-market: 2.280.00000.00%16:05 EDT
Volume:574.53K
Turnover:1.34M
Market Cap:278.47M
PE:-3.76
High:2.43
Open:2.37
Low:2.27
Close:2.40
Loading ...

Company Profile

Company Name:
OmniAb, Inc.
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
114
Office Location:
5980 Horton Street,Suite 600,Emeryville,California,United States
Zip Code:
94608
Fax:
- -
Introduction:
OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

Directors

Name
Position
Matthew W. Foehr
President, Chief Executive Officer and Director
John Higgins
Chairperson of the Board
Carolyn Bertozzi
Director
Jennifer Cochran
Director
Joshua Tamaroff
Director
Sarah Boyce
Director
Sunil Patel
Director

Shareholders

Name
Position
Matthew W. Foehr
President, Chief Executive Officer and Director
Kurt A. Gustafson
Executive Vice President, Finance and Chief Financial Officer
Charles S. Berkman
Chief Legal Officer and Secretary